Piramal Enterprises Limited Fundamentals

    Piramal Enterprises Limited operates pharmaceutical and financial services businesses in India, North America, Europe, Japan and internationally, operating across the pharmaceutical and financial services manufacturing and service segments. in non-real estate sectors. It also offers home loans to individual clients; building a retail lending platform; and engage in investment activities. In addition, the company offers contract development and manufacturing solutions throughout the entire drug lifecycle, including drug discovery, manufacturing and manufacturing of active pharmaceutical ingredients and formulations; as well as inhalation and parenteral anesthetics, injections for pain relief, antibiotics and other drugs, as well as drugs for intramedullary spasticity. 

    In addition, it offers over-the-counter products such as pain relievers, skin care products, vitamins and supplements, children's health, digestion, health and feminine hygiene. and is protected primarily under the trade names Saridon, Lacto Calamine, IPill, Supradyn, Polycrol and Tetmosol. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. The headquarters are located in Mumbai, India.

    Products and services offered by the Company

    The company is engaged in the production and sale of cement and related products.

    Piramal Pharma

    Pharma Solutions
    Critical Care
    Consumer Products

    Financial Services

    Piramal Capital & Housing Finance
    India Resurgence Fund (IndiaRF)

    Awards & Recognitions

    For Financial Services

    Piramal Capital & Housing Finance Limited was awarded Best Overall Investment Manager for Real Estate in India at the 15th Annual Euromoney Real Estate Survey 2019 - September 2019.
    Piramal Capital & Housing Finance Limited won ?Best Private Equity Deal of the Year at the 11th Estate Awards by Franchise India - August 2019.
    Piramal Capital & Housing Finance Limited was awarded ?Best In-House Legal Team of the Year in the Banking and Financial Services sector at the Asian Legal Business India Law Awards 2020 - March 2020.

    For Pharma

    Piramal Pharma Solutions was honored with the ?Frost & Sullivan Global Customer Service Leadership Award - June 2019.
    Piramal Pharma Solutions was ranked 1st by Biospectrum India in Bio Services - October 2019.
    Piramal Pharma Solutions won the ?2020 Manufacturing Supply Chain Operational Industry Excellence Award within the Pharmaceuticals Category at the 9th Edition of Manufacturing Supply Chain Awards - March 2020. 


    1980: In the early 1980s a young Ajay Piramal takes the reins of the Piramal Group.
    1984: Acquired Gujarat Glass
    1988: Acquired Nicholas Laboratories.
    1990: Gujarat Glass is merged with the group company, Nicholas Piramal India Ltd
    1991: A new formulation plant at Pithampur in Madhya Pradesh is commissioned.
    1992: Set up a second formulation plant at Pithampur in Madhya Pradesh with state-of-the-art manufacturing facilities.
    1992: Nicholas Laboratories Ltd. renamed to Nicholas Piramal India, Ltd.
    1993: Piramal entered into a joint venture agreement with Allergan of U.S.A., the leading manufacturers of Ophthalmic products.
    1994: A joint venture agreement was entered into with Satelec, France for dental care products.
    1995: The bulk drug division of Sumitra Pharmaceutical and Chemicals Ltd. Hyderabad transferred to NPIL.
    1996: Entered into a product tie-up with F. Hoffman-La-Roche.
    1996: Boehringer Mannheim is acquired.
    1997: NPIL entered into an agreement with Reckitt & Colman for joint marketing of the latter''s OTC products in India.
    1998: Acquired the research unit of Hoechst Marion Roussel (India) in Mumbai.
    1998: Nicholas Piramal India Ltd (NPIL) forges joint venture with Boots Healthcare International (BHI) to develop and market consumer healthcare products in India.
    2000: Rhone Poulenc India Limited is acquired.
    2000: Started collaborative research with Centre for Biochemical Technology in the field of gene technology.
    2000: Research alliance established with Hindustan Lever for developing Cosmoceuticals and personal care products.
    2002: ICI Pharma is acquired.
    2003: Global Bulk Drugs is acquired.
    2004: Nicholas forges alliance with scientists from Imperial College of the UK to carry out research in the field of rheumatoid arthritis.
    2005: Avecia Pharmaceutical is acquired.
    2006: Pfizer''s Morpeth UK facility acquired.
    2007: Scientists from Piramal led the first exploration by an Indian pharmaceutical company to develop drug leads from geographies like Antarctica.
    2008: Khandelwal Laboratories is acquired.
    2009: RxEliteinc, the U.S. based inhalation anesthetic gas distribution business, is acquired.
    2010: Biosyntech, Inc., Canada is acquired by Piramal Enterprises Ltd., part of the Life Sciences vertical, Bio-Orthopedics division.
    2010: Piramal sells the diagnostics division to Super Religare Laboratories Ltd.
    2010: Acquisition of iPill, an oral contraceptive brand, from Cipla.
    2011: Bharat Serum and Vaccines Ltd - Anaesthetics business buyout by Piramal Enterprises Ltd.
    2011: Piramal Realty acquires Mafatlal Mills in Byculla, Mumbai.
    2011: Piramal Healthcare acquires 11% of Vodafone India.
    2011: UN Conference on Trade and Development’s World Investment Report 2011 ranks Piramal Healthcare as No. 5 in the top 10 pharmaceutical contract manufacturers worldwide.
    2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
    2011: Fortune 500 ranks Piramal Healthcare in the top-50 largest corporations across India.
    2011: Piramal''s Pharma Solutions manufacturing site at Grangemouth, Scotland becomes the world’s first contract supplier at commercial scale for ADCs.
    2011: Piramal Healthcare acquires Indiareit, a real estate focused investment trust with AUM of $760 million.
    2012: Piramal Realty wins the auction of the landmark Hindustan Unilever training centre at Worli Sea Face, Mumbai.
    2012: Decision Resources Group acquires Abacus International, a UK based global market access solutions company for many of the world’s leading health care companies.
    2012: BST-CarGel, company’s innovative bio-orthopedic product for cartilage repair, receives European CE mark approval.
    2012: Piramal Enterprises starts a Non-Banking Financial Company (NBFC) focused on lending to real estate, education and hospitals
    2012: Piramal Enterprises acquires health care information management firm, Decision Resources Group, USA for US$635 million
    2012: Piramal Realty, a privately owned real estate entity, was formed
    2012: Piramal Healthcare Limited is renamed to Piramal Enterprises Limited.
    2013: Piramal Enterprises Limited acquires Molecular Imaging Development portfolio of Bayer Pharma
    2013: Imaging division''s lead radiopharmaceutical, Florbetaben, accepted for review by the US FDA and EMA for the visual detection of Beta-Amyloid in Alzheimer''s disease
    2013: Piramal Water (Sarvajal) honoured with ''Enabling Technology Award of the Year 2013'' by Frost & Sullivan
    2013: Piramal Enterprises Ltd. consumer products'' division acquires the brand CALADRYL® in India.
    2014: APG Asset Management, the Dutch pension fund asset manager and Piramal Enterprises Limited announce a strategic alliance for investing in rupee denominated mezzanine instruments issued by infrastructure companies in India with a target investment of US$1 billion, over the next 3 years
    2014: Piramal Enterprises Limited acquires 9.99% equity stake in Shriram City Union Finance Limited
    2014: Piramal Enterprises Limited agrees to acquire an effective 20% equity stake in Shriram Capital Limited, a financial services company, for an aggregate consideration of INR 20.14 Billion
    2014: Canada Pension Plan Investment Board (CPPIB) and Piramal Enterprises Limited announce a US$500 million Strategic Alliance for Residential Development Debt Financing in India; appoint Piramal Fund Management (at the time known as Indiareit) as advisor
    2015: Piramal Enterprises Ltd. acquires Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laboratories Inc.
    2015: DRG has acquired Healthcare Business Insights (HBI), a trusted provider of best Practice research, training and services to more than 1,400 hospitals across the U.S.
    2015: Warburg Pincus to invest Rs 1800 crore in Piramal Realty.
    2015: Piramal Realty secures $150 million (Rs 900 crore) from Goldman Sachs.
    2015: Piramal Realty launches a new community for natural and holistic living at Balkum, Thane, Mumbai: Piramal Vaikunth
    2015: Piramal Enterprises acquires the Baby Care brand – Little’s for the Consumer Products Business
    2016: Piramal Enterprises announces the sale of its Canada-based cartilage repair product, BST-CarGel® to Smith & Nephew
    2016: Piramal Realty launches its signature project, Piramal Aranya in Byculla, Mumbai
    2016: Piramal Enterprises enters an agreement to acquire four brands from Pfizer Limited for its Consumer Products Business
    2016: Piramal Realty forays into commercial real estate with the launch of Piramal Agastya Corporate Park in Kurla, Mumbai
    2016: Piramal Enterprises enters into an agreement to acquire Ash Stevens Inc., a US based Contract and Drug Manufacturing Organisation (CDMO) for High Potency APIs (HPAPIs)
    2016: Piramal Enterprises Limited and Bain Capital Credit to pursue distressed debt investing in India
    2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen''s Injectable Anaesthesia and Pain Management products
    2016: Piramal Enterprises Critical Care Division expands its product portfolio; enters into an agreement to acquire Janssen''s Injectable Anaesthesia and Pain Management products
    2016: Piramal Fund Management launches an Innovative Flexi Lease Rental Discounting (LRD) for Commercial Assets.
    2017: Piramal Enterprises Limited announces its plan to enter Housing Finance
    2017: Piramal Enterprises Limited and Ivanhoé Cambridge announce Partnership to Invest in Residential Developments in India
    2017: Piramal Realty marks exclusive pre-Launch of Piramal Revanta
    2017: Piramal Enterprises Completes the Acquisition of a Portfolio of Drugs for Spasticity and Pain Management from Mallinckrodt LLC.
    2018: Piramal Finance Limited Forays into the Hospitality Sector
    2018: Piramal Realty launches Piramal Mahalaxmi, its Flagship Project in South Mumbai
    2018: NITI Aayog Partners with Piramal Foundation to Transform 25 Aspirational Districts across 7 states in India, in the areas of Health & Nutrition and Education.
    2018: IndiaRF Announces $156 million Investment in Archean Group’s Marine Chemicals Business.
    2019: Piramal Enterprises Limited signed a Memorandum of Understanding with Canada Pension Plan Investment Board (CPPIB) to set-up Asset Aggregation Platform focused on renewables.
    2019: Supreme Court Exempts Saridon from the List of Banned FDCs.
    2019: Piramal Swasthya has been recognized by USAID with the ‘Inclusive Health Access Award’ for its High Impact Healthcare Platform
    2019: Piramal Foundation and Gates Foundation Partner to Setup a Tribal Health Collaborative for India
    2019: Piramal Swasthya and The Rockefeller Foundation Announce Partnership to Accelerate India’s Public Health Transformation
    2019: Piramal Divests its DRG Business for $950 million.
    2019: PEL raises funds of Rs 14,500 crore in FY2020.
    2019: Piramal Realty Makes a Foray into Value Housing Segment
    2020: Piramal Group Commits INR 25 Crores to COVID-19 Relief Effort.
    2020: Carlyle and Piramal Pharma Sign Agreement on 20% Strategic Growth Investment.

    Piramal Enterprises Limited Stock Price Analysis and Quick Research Report

    Let’s scrutinize however PEL is acting and if it's the proper time to buy the stock of PEL with careful analysis.

    Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2,256.67 Cr.
    Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Piramal Enterprises has a Debt to Equity ratio of 0.29 , which is a strong indication for the company.
    EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Piramal Enterprises , the EPS growth was -72.45 % which is bad for the company.
    Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Piramal Enterprises has OPM of 40.58 % which is a good sign for profitability.
    ROE: Piramal Enterprises have a poor ROE of 0.17 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.


    PEL Mini Live Chart


    PEL Technical 

    NOTE: We might update this page with latest updates/information/news etc if it deems to be necessary.

    Thank You

    To Top